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August 2016Randomized clinical trials conducted over the past 20
years have consistently demonstrated that the aggressive
reduction of low-density lipoprotein cholesterol (LDLC)
with statin therapy reduces cardiovascular risk in the
settings of secondary prevention and high-risk primary
prevention. When used as an adjunct to lifestyle
interventions, statin therapy can be expected to reduce
the rates of major coronary events by 24% for each
1-mmol/L reduction in LDLC (hazard ratio [HR] 0.76, 95%
CI 0.73-0.79), stroke by 15% (HR 0.85, 95% CI 0.80-0.89),
and coronary revascularization by 24% (HR 0.76, 95% CI
0.73-0.79).1,2 Meta-analyses, however, also demonstrate
that relative risk reductions with statin therapy are not
related to baseline levels of LDLC. Rather, trial data as well
as observational, ecologic, and genetic studies suggest that
ever lower LDLC levels are likely to confer cardiovascular
benefits regardless of starting cholesterol levels for an
individual patient.3-6 If anything, the greatest relative risk
reductions observedwith statin therapy accrue among those
with lower rather than higher levels of absolute vascular risk,
data consistent with the biologic view that aggressive
reductions in circulating atherogenic lipids early in the
disease process are likely to produce the greatest clinical
benefits.7 Low-density lipoprotein cholesterol reduction
with statin therapy has also proven highly effective for
reducing vascular risk in those with diabetes8 and in some
cases can lead to regression of coronary atherosclerosis.9
For individual patients, however, variability in LDLC
response to statin therapy is exceptionally wide.10 For
example, in the JUPITER primary prevention trial where
all individuals received a high-intensity statin regimen,
fewer than half of the subjects achieved LDLC reductions
greater than 50%, yet the magnitude of percentage
change in LDLC was directly related to subsequent
event rates.11 Although the addition of ezetimibe to
moderate dose statin therapy further reduced LDLC and
clinical events in the contemporary secondary prevention
IMPROVE-IT trial, the rate of recurrent vascular events in
that study still exceeded 30% over the mean follow-up of
5.4 years.4 Last, not all patients tolerate statin therapy. It
has thus long been recognized that effective and safe
treatments for residual cholesterol risk are needed, not
only for those with a history of cardiovascular events but
also for primary prevention patients at high vascular risk.
Bococizumab is a humanized monoclonal antibody that
inhibits proprotein convertase subtilisin-kexin type 9
(PCSK9), preventing PCSK9-mediated degradation of the
LDL receptor.12,13 In a dose-finding study among
statin-tolerant patients, bococizumab substantially low-
ered LDLC when given at a regimen of 150 mg every 2
weeks,14 data consistent with those of other monoclonal
antibodies that interfere with the LDL receptor binding
domain of PCSK9.15,16
To comprehensively address the efficacy and safety of
bococizumab in broad patient populations at risk for
cardiovascular events, the SPIRE development programwas designed to include 6 lipid-lowering studies and 2
large-scale, event-driven, cardiovascular outcomes trials
(SPIRE-1 and SPIRE-2), each comparing bococizumab
(150 mg subcutaneously [SC] every 2 weeks) to matching
placebo. As described here, the SPIRE program involves
more than 30,000 individuals worldwide and will (a)
formally ascertain the magnitude of reduction in athero-
genic lipids that accrue with bococizumab and (b)
determine whether the addition of this PCSK9 inhibitor
to standard treatment significantly reduces cardiovascular
morbidity and mortality in high-risk patients, including
those without a history of clinical cardiovascular events.
Methods
Overview
The SPIRE program and the research described in this
article are sponsored by Pfizer, Inc (New York, NY). The
SPIRE bococizumab development program consists of 2 parts,
the SPIRE lipid-lowering studies and the SPIRE-1 and SPIRE-2
event-driven cardiovascular outcomes trials (Figure 1). The
protocols for each SPIRE study were designed through a
collaboration between academic members of the SPIRE
Executive and Steering Committees and physician and
statistician employees of the sponsor (Pfizer). Each
protocol was approved at participating centers by the
responsible institutional reviewboard or ethics committee,
as applicable in the 37 countries involved in the SPIRE
program. A single fully independent Data Monitoring
Committee oversees safety monitoring of all SPIRE studies.
Each SPIRE study has a prespecified statistical analysis plan
reviewed by the trial Executive Committee. Academic
researchers as well as an independent academic statistician
at the Center for Cardiovascular Disease Prevention,
Brigham and Women's Hospital, Harvard Medical School,
will have full access to the trial databases and will have
independent responsibility for generating trial analyses for
publication. The authors of all SPIRE manuscripts will be
solely responsible for drafting and editing of manuscripts
and their final contents. As prespecified in the SPIRE
Publication Charter, should any disagreements arise
between the sponsor and the academic leadership, final
decisions for publication shall lie with the academic
members of the SPIRE Executive Committee.
The SPIRE lipid-lowering program
The SPIRE lipid-lowering program (Figure 1, left)
consists of 6 parallel multinational studies known as
SPIRE-HR (NCT01968954, which includes 711 hyperlip-
idemic patients on maximally tolerated statin therapy at
high risk for cardiovascular events), SPIRE-LDL
(NCT01968967, which includes 2139 hyperlipidemic
patients on maximally tolerated statin therapy with
multiple cardiovascular risk factors and directly measured
LDLC ≥70 mg/dL), SPIRE-FH (NCT01968980, which
includes 370 individuals with heterozygous familial
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Volume 178hypercholesterolemia), SPIRE-SI (NCT02135029, which
includes 184 individuals with hyperlipidemia who were
statin intolerant), SPIRE-LL (NCT02100514, which includes
746 individuals receiving statin therapy who had residual
directly measured LDLC levels ≥100 mg/dL where
additional lipid lowering was under consideration), and
SPIRE-AI (NCT02458287, which includes 299 individuals
with LDLC ≥70 mg/dL measured directly where bococi-
zumab delivery is given with an auto-injector device).
In SPIRE-HR, SPIRE-LDL, SPIRE-FH, and SPIRE-LL,
eligible participants underwent identical baseline lipid
evaluations, were randomly allocated (in a 1:1 ratio,
except for SPIRE-LL which used a 2:1 ratio) to either
bococizumab 150 mg SC every 2 weeks or to matching
placebo, and were then followed up prospectively for 1
year. In SPIRE-SI, eligible participants were randomly
allocated in a 2:1:2 fashion to bococizumab 150 mg SC
every 2 weeks, atorvastatin 40 mg per os daily, or
matching placebos, and were then followed up prospec-
tively for 6 months. In all of these studies, participants
were trained to self-administer study drug through
subcutaneous injections, and study drug was adminis-
tered by study site personnel only in rare circumstances
where neither the patient nor a home caregiver or family
member was capable of performing this task. By contrast,
in SPIRE-AI, eligible participants were randomly allocated
to bococizumab or matching placebo delivered with an
auto-injector device and were followed up for 12 weeks;
in this study, a 75-mg SC dose every 2 weeks was
evaluated as well as the 150-mg dose used in the other
SPIRE studies. Participants were randomized 2:2:1:1 to
bococizumab 150mg SC every 2weeks, bococizumab 75mg
SC every 2 weeks, matching placebo 150 mg, or matching
placebo 75 mg.
In the SPIRE-HR, SPIRE-LDL, and SPIRE-LL studies, an
identical protocol was used that included a 4-weekprerandomization screening period to verify eligibility
and ensure that patients had been and are continuing to
receive maximally tolerated statin dosing. In these trials,
participants were stratified by geographic region and by
prerandomization triglyceride levels (b or ≥200 mg/dL).
Blood specimens were obtained at the face-to-face visits
which were scheduled at baseline and at weeks 4, 8, 12,
24, 36, 48, and 52 and at study completion (Figure 2). A
virtually identical protocol was followed in SPIRE-FH,
with the exception that stratification by triglyceride
levels was not performed. The SPIRE-SI protocol was
again similar in structure, but enrolled only individuals
with a history of statin intolerance due to muscle related
symptoms, was stratified by country, and included a statin
rechallenge arm (atorvastatin 40 mg daily). In the
12-month duration trials, protocol-driven dose reductions
of bococizumab from 150 mg SC every 2 weeks to 75 mg
SC every 2 weeks were triggered by the observation of
directly measured LDLC levels ≤10 mg/dL (0.26 mmol/L)
on 2 consecutive visits, with sham dose modifications
made in the placebo group to maintain study blind. If
directly measured LDLC levels remained in this range
during continued follow-up, a second protocol-driven
dose reduction of bococizumab (or matching placebo) to
75 mg every 4 weeks was made. In all studies, a 6-week
follow-up visit off study drug was conducted after the end
of the treatment period to systematically ascertain for any
untoward effects.
The primary prespecified end point in all SPIRE
lipid-lowering trials is the percent change from baseline
in fasting LDLC measured with a direct assay at week 12,
whereas long-term persistence of any effects on LDLC
was also evaluated throughout the 1-year follow-up
period for the longer-term studies. Secondary prespeci-
fied, type 1 error–controlled end points are the percent
change in total cholesterol, apolipoprotein B, non–
Figure 2
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August 2016high-density lipoprotein cholesterol (non-HDLC), lipo-
protein(a), and HDLC at week 12. Type 1 error will be
controlled using a combination of fixed sequence testing
and the Hochberg procedure. Other prespecified end
points include the percent change in apolipoprotein AI,
apolipoprotein AII, very low density lipoprotein choles-
terol, triglycerides, and, in the 12-month studies, high--
sensitivity C-reactive protein (hsCRP). All plasma samples
are to be obtained after a minimum 10-hour fast, and all
plasma assays are performed in a central core laboratory.
Levels of LDLC are assessed both directly and as a
calculated value with the use of the Friedewald formula.
Data from the 6 SPIRE lipid-lowering studies will be
analyzed separately and combined into a single analysis
set. Baseline demographic and lipid data will be
summarized with the use of proportions for categorical
variables, and medians (interquartile ranges) for contin-
uous variables. Initial comparisons between treatment
groups in the distributions of percent change at 12 weeks
will use the Wilcoxon rank sum test, with accompanying
Hodges-Lehman estimate of the location shift between
groups with 95% CI. As specified in the individual
protocols for each trial, the estimates of the treatment
effect, its 95% CI, and P-value for comparison with
placebo come from the primary analysis model, a
repeated-measures, mixed linear model regression, esti-
mated by restricted maximum likelihood. Each model
will contain the following fixed effects: treatment
(categorical variable), scheduled visit time point (cate-
gorical variable), baseline LDLC, interaction between
treatment and scheduled visit time point, interaction
between baseline LDLC and scheduled visit time,
geographic region (country in SPIRE-SI; categorical
variable), and prerandomization triglyceride level (≤ or
N200 mg/dL, categorical variable in SPIRE-LL, SPIRE-LDL,
and SPIRE-HR only). The default covariance structure is
unstructured (except spatial power in SPIRE-SI), with
alternative covariance structures specified in each
protocol in case of convergence problems. The individual
estimates of treatment effects at 12 weeks will be
combined in a random-effects meta-analysis, using the
approach of Dersimonian and Laird.17 Safety analyses forspecific adverse events will present incidence rates for
the bococizumab and placebo groups along with 95% CIs
on the incidence rates calculated using an exact
Clopper-Pearson method for Poisson random variables.
In addition, incidence rates will be combined across
studies resulting in a rate ratio comparing bococizumab
with placebo along with the exact CI for this rate ratio.
Adverse events occurring in ≥2% of subjects in either
treatment group will be highlighted.
In addition to changes in lipid levels, clinical data from
the five SPIRE lipid-lowering trials with treatment
duration of 6 months or more will be pooled to allow
for a prespecified exploratory safety assessment of
bococizumab as compared with placebo of the incidence
of adjudicated cardiovascular events occurring after the
time of randomization. Specific events contributing to the
composite end point in this analysis are the first
occurrence of nonfatal myocardial infarction, nonfatal
stroke, hospitalization for unstable angina requiring
urgent revascularization, other coronary revasculariza-
tion procedures, or cardiovascular death. For the
primary analysis, the composite end point will be
analyzed using a log-rank statistic to compare the 2
treatment groups. The HR and the corresponding 95%
CI will be estimated using a Cox proportional hazards
model. As a supplemental assessment, the composite
end point will be analyzed using a log-rank statistic
stratified by study and the HR and 95% CI will be
estimated using a Cox proportional hazards model
stratified by study. All analyses will be conducted on an
intention-to-treat basis, all P values 2 tailed, and all CIs
computed at the 95% level.
The SPIRE-1 and SPIRE-2 cardiovascular outcome trials
The SPIRE cardiovascular outcomes program consists
of SPIRE-1 (NCT01975376) and SPIRE-2 (NCT01975389),
2 parallel, multinational, randomized, placebo-controlled
event-driven trials of bococizumab given at a dose of 150
mg SC every 2 weeks (Figure 1, right). To ensure
evaluation of bococizumab among a representative
population, each SPIRE cardiovascular outcome trial
will enroll individuals across a broad range of cardiovas-
cular risk, including patients with and without a history of
clinical cardiovascular disease. All patients will be treated
with an aggressive regimen of highly effective statin
therapy (defined per protocol as the stable use for at least
the past 4 weeks of atorvastatin ≥40 mg daily,
rosuvastatin ≥20 mg daily, or simvastatin ≥40 mg daily)
or demonstrate intolerance to high-intensity therapy (and
be treated with a lower-intensity regimen) or, in the case
of SPIRE-2, demonstrate complete statin intolerance
(defined as documented failure to tolerate at least 2
different statin agents including one at the lowest
available daily dose, or having a documented history of
statin-induced rhabdomyolysis or statin-induced allergic
reaction precluding rechallenge).
Table. Comparison of the SPIRE-1, SPIRE-2, FOURIER, and ODYSSEY Outcomes PCSK9 clinical trials
SPIRE 1
(n = 17,000)
SPIRE 2
(n = 11,000)
FOURIER
(n = 27,500)
ODYSSEY Outcomes
(n = 18,000)
Monoclonal antibody Bococizumab (humanized)
150 mg Q2W
Bococizumab
(humanized)
150 mg Q2W
Evolocumab (human)
140 mg Q2W
Alirocumab (human)
75-150 mg Q2W
420 mg Q4W
Entry LDLC (mg/dL) ≥70 ≥100 ≥70 ≥70
Statin requirement Atorvastatin 40 or 80 mg High-intensity statin
preferred, minimum
dose atorvastatin
20 mg or equivalent
Atorvastatin 40 or 80 mg
Rosuvastatin 20 or 40 mg Rosuvastatin 20 or 40 mg
or the maximum tolerated
dose of one of these agents
Simvastatin 40 mg (or 80 mg if N1 year) or
documented intolerance to high intensity statin
(SPIRE-1 and SPIRE 2) or documented complete
statin intolerance (SPIRE-2)⁎
High-risk secondary
prevention
Yes Yes Yes Yes
High-risk primary prevention Yes Yes No No
⁎Allowed not to be taking statin if intolerant to any 2 statins (one at lowest dose) or a history of statin-induced rhabdomyolysis.
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Volume 178The SPIRE-1 trial will recruit 17,000 individuals with
directly measured LDLC levels of≥70 mg/dL (1.81 mmol/
L), and the SPIRE-2 trial will recruit 11,000 individuals
with directly measured LDLC levels ≥100 mg/dL (2.59
mmol/L). In recognition of the emerging importance of
non-HDLC, patients are also eligible for SPIRE-1 if they
have entry non-HDLC levels ≥100 mg/dL (2.59 mmol/L)
and for SPIRE-2 if they have entry non-HDLC levels ≥130
mg/dL (3.36 mmol/L).
In addition to these entry LDLC and non-HDLC criteria,
patients are eligible for SPIRE-1 and SPIRE-2 if they have a
history of a cardiovascular event (secondary prevention
cohort, defined as prior myocardial infarction, prior
ischemic stroke, or prior coronary artery, or peripheral
artery revascularization) or have a history of diabetes,
chronic kidney disease, or peripheral vascular disease
with additional cardiovascular risk conditions or risk
factors, or a history of familial hypercholesterolemia
(high-risk primary prevention cohort). To augment risk
for the primary prevention cohort, individuals typically
also have one or more additional risk factors such as
smoking, levels of HDLC b40 mg/dL (1.03 mmol/L), levels
of hsCRP N2.0 mg/L, levels of lipoprotein(a) N50 mg/dL,
evidence of microalbuminuria, or evidence by cardiac
imaging of asymptomatic coronary stenosis, and must be
≥50 years of age for men and≥60 years of age for women
(except if they have a history of familial hyperlipidemia,
in which case the minimum age is 35 years for men and
45 years for women). With the exception of the entry
lipid levels, the formal inclusion criteria for the SPIRE-1
and SPIRE-2 trials are virtually identical and are outlined in
online Supplementary Table 1.
Patients are excluded from SPIRE-1 and SPIRE-2 if the
qualifying vascular event was less than 30 days prior to
screening (and b90 days for coronary revascularization)
or if they have not yet completed planned coronaryrevascularization procedures. Other major exclusion
criteria are the presence of New York Heart Association
class IV congestive heart failure or known left ventricular
ejection fraction b25%, end-stage renal disease on dialysis,
creatinine clearance b30 mL min−1 1.73 m−2, poorly
controlled hypertension, a history of hemorrhagic stroke,
known hypersensitivity to monoclonal antibodies, a
current cancer treatment, planned or previous gastric
bypass surgery, creatine kinase levels ≥3 times the upper
limits of normal (ULN), alanine transaminase or aspartate
transaminase N2 times ULN, direct bilirubin N1.5 times
ULN, or the presence of conditions that might reduce the
likelihood of long-term study adherence and compliance.
The formal exclusion criteria for the SPIRE-1 and SPIRE-2
trials are virtually identical and are outlined in online
Supplementary Table 2.
In both SPIRE-1 and SPIRE-2, eligible patients enter a
6-week placebo run-in period designed to ensure
compliance with SC drug administration. Participants
are then randomized in a double-blind manner to either
bococizumab (150 mg SC every 2 weeks) or matching
placebo. As in the SPIRE lipid-lowering studies, proto-
col-driven dose reductions of bococizumab from 150 to
75 mg SC are triggered by the observation of LDLC levels
b10 mg/dL (0.26 mmol/L) on 2 consecutive visits, with
sham dose modifications made in the placebo group to
maintain study blind. In addition, in both trials a further
protocol-driven dose reduction for bococizumab (or
matching placebo) from 75 mg SC every 2 weeks to
every 4 weeks is triggered by the observation of LDLC
levels b10 mg/dL (0.26 mmol/L) on 2 further consecutive
study visits.
Once randomized, all SPIRE-1 and SPIRE-2 participants
will be followed up prospectively for incident cardiovas-
cular events and adverse effects until study completion.
Figure 3 outlines the key phases of the parallel SPIRE-1
Figure 3
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August 2016and SPIRE-2 trials. In each case, randomized participants
return for study visits at weeks 4, 8, 14, and 26, and then
at 12- to 18-week intervals until completion. Baseline and
on-study drug blood samples are collected in a standard-
ized manner and undergo lipid and safety evaluations in a
central core laboratory. Among consenting participants,
baseline and on-treatment blood samples are also stored
for future biomarker and genetic studies. Study sites are
asked to avoid nontrial ascertainment of lipid levels
during the study and changes in postrandomization statin
dosing are discouraged.
Safety will further be assessed through adverse events
and serious adverse events collection, vital signs, physical
examination results, 12-lead electrocardiogram record-
ings, and safety laboratory tests including hematology,
blood chemistry studies (including liver function tests
and creatine kinase tests), urinalysis studies, and antidrug
antibody assessments. Neurocognitive function assess-
ments, as outlined in online Supplementary Table 4, are
planned in a substudy of approximately 500 subjects in
each of the SPIRE-1 and SPIRE-2 trials.
The prespecified primary end point of both SPIRE
outcome trials is a composite of adjudicated and
confirmed nonfatal myocardial infarction, nonfatal
stroke, hospitalization for unstable angina requiring
urgent revascularization, or cardiovascular death. The 4
key secondary end points are (a) the composite of
nonfatal myocardial infarction, nonfatal stroke, and
cardiovascular death; (b) the composite of nonfatal
myocardial infarction, nonfatal stroke, and all-cause
mortality; (c) the composite of nonfatal myocardial
infarction, nonfatal stroke, all-cause mortality, and
hospitalization for unstable angina needing urgent
revascularization; and (d) hospitalization for unstable
angina needing urgent revascularization. Type 1 error will
be controlled using fixed sequence testing. All incident
clinical events that are components of the primary or key
secondary end points are adjudicated by a clinical end
point committee unaware of study drug allocation using
standardized criteria defined by the US Food and DrugAdministration for cardiovascular outcome trials.18 A full
listing of all prespecified primary and secondary end
points for the SPIRE cardiovascular outcome trials is
provided in online Supplementary Table 3. All SPIRE
participants are followed up for adverse events, with
particular emphasis on muscle-related symptoms, inci-
dent diabetes, cognitive function, and laboratory changes
in liver function, estimated glomerular filtration rate,
creatine kinase, glucose, hemoglobin A1c, hsCRP, and
anti-bococizumab antibodies.
Efficacy analyses in SPIRE-1 and SPIRE-2 will be
conducted on an intention-to-treat basis, and safety
evaluations will include any participant who received at
least one dose of randomized study drug. The trial sample
size for SPIRE-1 (n = 17,000, event driven for an
anticipated 844 participants with an adjudicated and
confirmed primary end point) should provide approxi-
mately 90% power to detect a 20% relative risk reduction
in the trial primary end point, assuming a background
annual event rate of at least 2.3% per year, a 1% per year
premature discontinuation rate, and a trial duration of
approximately 4.8 years. The trial sample size for SPIRE-2
(n = 11,000, event driven for an anticipated 508
participants with an adjudicated and confirmed primary
end point) should provide approximately 90% power to
detect a 25% relative risk reduction in the trial primary
end point, assuming a background annual event rate of at
least 2.7% per year, a 1% per year premature discontin-
uation rate, and a trial duration of 3.9 years. These trial
durations include a requirement to continue each study
until at least one year after the last randomization in that
study.
In SPIRE-1 and SPIRE-2, the primary end point will be
analyzed using a log-rank test stratified by geographic
region. In SPIRE-1, additional stratification for baseline
LDLC levels (b100 or ≥100 mg/dL) will be performed,
whereas in SPIRE-2, additional stratification according to
complete statin intolerance will be performed. Hazard
ratios and 95%CIswill be computed in each trial following
these stratification criteria using Cox proportional hazards
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ascertained.
In addition to the main efficacy analyses, both SPIRE-1
and SPIRE-2 will address the percent change and nominal
change from baseline to week 14 for a panel of lipid
biomarkers including LDLC, non-HDLC, total cholesterol,
triglycerides, very low density lipoprotein cholesterol,
remnant lipoprotein cholesterol, apolipoprotein B, apo-
lipoprotein A-I, and lipoprotein(a), as well as hsCRP.
Methods for analysis of lipid and other biomarker changes
in the SPIRE-1 and SPIRE-2 trials are also prespecified in
the trial protocols and parallel those being used in the
SPIRE lipid-lowering program as described above. Data
on health care resource utilization will be ascertained
throughout the trial period.
In addition to the above, guidelines are in place that
would allow the independent Data Monitoring Commit-
tee, if it electively chose to do so, to consider early
termination of the smaller SPIRE-2 trial for clinical efficacy
after 75% of the anticipated primary end point and first
key secondary end point events had accrued. Consider-
ation of early termination for efficacy would only occur if
the observed relative risk reduction for the primary end
point and for the first key secondary end point is
substantially greater than anticipated in the power
calculations (at least 28.62% for the primary end point
and 36.09% for the key secondary end point), is
statistically extreme (P values of b.001 for both end
points), and is consistent across geographic regions and
major clinical subgroups. To control the overall α, the
final α will be reduced by .00002. Early termination of
SPIRE-2 is elective at the discretion of the Data
Monitoring Committee and would only be considered
if, in addition to the above, there is no excess of
noncardiovascular mortality and no apparent safety issues
for which additional data are deemed critical. To ensure
adequate long-term exposure and safety evaluations in
the bococizumab development program, no early stop-
ping guidelines for clinical efficacy exist for the larger
SPIRE-1 trial which is inclusive of 17,000 patients.
The SPIRE lipid-lowering and SPIRE cardiovascular
outcomes trials are funded by Pfizer, New York, NY.Discussion
Residual cholesterol risk among statin-treated patients
and among statin-intolerant patients is a clinical concern
in secondary prevention and in high-risk primary
prevention. As described here, the SPIRE development
program is designed to address the magnitude of
additional LDLC reduction that can be achieved with
bococizumab (150 mg SC every 2 weeks) in both of these
broad patient groups, and to evaluate the long-term
clinical efficacy and safety of this emerging treatment of
hyperlipidemia.SPIRE is one of 3 ongoing phase 3 programs evaluating
monoclonal antibodies to PCSK9 in the prevention of
cardiovascular events (Table). For example, the FOURIER
trial of evolocumab (NCT01764633) is enrolling 27,500
secondary prevention patients (including those with
symptomatic peripheral vascular disease) with LDLC
≥70 mg/dL,19 whereas the ODYSSEY Outcomes trial of
alirocumab (NCT01663402) is enrolling 18,000 patients
after acute coronary syndromes with LDLC≥70 mg/dL.20
Thus, although there is overlap between programs, only
the SPIRE bococizumab program is additionally evaluat-
ing the efficacy and safety of PCSK9 inhibition in an
asymptomatic high-risk primary prevention cohort of
individuals with diabetes, chronic kidney disease, or
familial hypercholesterolemia but no known evidence of
clinically evident atherosclerosis, as well as in those with
complete statin intolerance. The SPIRE-2 trial, by limiting
enrollment to those with LDLC ≥100 mg/dL, will also
provide the largest efficacy and safety database for any
PCSK9 inhibitor in this population that has been unable
to reduce LDLC below this clinical threshold despite
aggressive use of statin therapy and/or ezetimibe. Other
potential differences between programs include the facts
that evolocumab and alirocumab are fully human
antibodies to PCSK9 that use incomplete binding to the
LDL-receptor binding site, whereas bococizumab is a
humanized PCSK9 antibody that provides near-complete
binding overlap of the LDL-receptor binding site of
PCSK9.13,21,22 With regard to effector function, bococi-
zumab also differs from evolocumab or alirocumab in that
it uses IgG2ΔA binding to theoretically reduce activation
of complement pathways. It is uncertain whether any of
these potential between drug differences substantively
matter in terms of clinical efficacy, safety, and tolerability.
Completed phase 2 trials for bococizumab, alirocumab,
and evolocumab have found these monoclonal antibodies
to PCSK9 highly effective in reducing LDLC when given
as monotherapy, as adjuncts to statin therapy with or
without ezetimibe, and among those with statin intoler-
ance.14,23-26 Monoclonal antibodies to PCSK9 are also
effective at reducing LDLC among individuals with
heterozygous familial hypercholesterolemia (for whom
there is reduced LDL-receptor activity)27,28 and for
patients with homozygous familial hypercholesterolemia
who are LDL-receptor defective, a clinical setting where
statin efficacy is limited.29,30 Preliminary data from the
evolocumab and alirocumab phase 2 trials further suggest
that PCSK9 inhibitors are promising agents for cardiovas-
cular event reduction,15,16 but questions must still be
addressed on long-term efficacy and safety.
To date, no major safety issues have been uncovered
withmonoclonal antibodies to PCSK9, although initial data
for alirocumab and/or evolocumab raise the possibility of
small increases inneurocognitive and opthalmalogic events
and potential small increases in arthralgia, headache, and
fatigue.15,16 Each of these is being closely followed in the
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programs for evolocumab and alirocumab, respectively,
the SPIRE program for bococizumab will also contribute
critical data related to long-term safety of achieving very
low levels of LDLC. In statin trials31,32 and in trials of
ezetimibe added to statin therapy, on-treatment levels of
LDLC below 40mg/dL have generally beenwell tolerated.4
However, because statins havebeen associatedwith a small
increase in risk of developing new-onset diabetes,33,34 all
ongoing PCSK9 programs including SPIRE are closely
monitoring this clinical end point. Theoretically very low
LDLC in the peripheral compartment could have effects on
hormone production and vitamins synthesized from
cholesterol. However, such effects have not been clinically
important with other PCSK9 inhibitors35 and individuals
with loss-of-function mutations of PCSK9 have been free of
apparent adverse effects on this basis.36,37 Nonetheless,
PCSK9 may mediate several functions independent of its
role in lipid homeostasis, such as trafficking of epithelial
sodium channel, hepatic regeneration, pancreatic integrity
and glucose homeostasis, antiviral activity, regulation of
different cell signaling pathways, cortical neural differen-
tiation, and neuronal apoptosis.38 To date, there is no
evidence that inhibition of PCSK9 in the management of
dyslipidemic patients is associated with such effects, but
the completion of large-scale trials as well as longer-term
observational studies will be needed to fully address
clinical safety.
In summary, the SPIRE development program for
bococizumab will involve more than 30,000 individuals
worldwide and will ascertain the magnitude of reduction
in atherogenic lipids that accrue with bococizumab and
determine whether the addition of this PCSK9 inhibitor
to standard treatment significantly reduces cardiovascular
morbidity and mortality in high-risk patients, including
those without a history of clinical cardiovascular events.
The SPIRE lipid-lowering trials and the SPIRE-2 trial are
fully enrolled, whereas enrollment into SPIRE-1 is
projected to complete by late 2016.Disclosures
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